Amphetamine Stimulant Prodrug denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits Quantity for This Amphetamine Prodrug

Humana, like most major insurers, imposes quantity limits on amphetamine-based stimulant prodrugs as a standard utilization-management tool. These limits are set by Humana's Pharmacy and Therapeutics committee and are intended to align dispensing with what the insurer considers clinically standard. A quantity-limit denial does not mean the drug is inappropriate for your patient — it means the amount requested exceeds the plan's preset threshold.

## Why This Denial Is Appealable

If your prescriber has documented a clinical rationale for the requested quantity — for example, a titration protocol, body-weight-based dosing rationale, or a history showing the standard quantity is insufficient — that documentation creates the foundation for a successful appeal. The FDA-approved prescribing information for this medication specifies the full approved dosing range; if the prescribed quantity falls within that range and the plan's limit is more restrictive, that gap is the crux of your argument.

## Federal Appeal Framework

• Internal appeal: Submit within the timeframe printed on your denial notice (typically 180 days for ERISA plans).
• External review (ACA §2719 / ERISA §503): After exhausting internal appeals, you have the right to an independent external review. The standard window is approximately four months from the date of the final internal denial. Expedited external review (typically 72-hour turnaround) is available when the standard timeline would seriously jeopardize the patient's health or ability to regain maximum function.
• State insurance department: For fully insured (non-ERISA) plans, your state's insurance commissioner can be an additional avenue.

## Concrete Appeal Steps and Timeline

1. Request the full denial rationale in writing — Humana must provide the specific plan criteria used. 2. Obtain Humana's current Drug Coverage/Formulary Policy for this medication, including the quantity-limit schedule. 3. Submit the internal appeal with supporting documentation within the stated deadline. 4. If denied internally, request external review within the ~four-month window.

## Documentation to Gather

• Diagnosis confirmation: Chart notes, diagnostic evaluations, and any relevant specialist assessments establishing the condition and its severity.
• Prescriber medical-necessity letter: The prescriber should explicitly state why the requested quantity is medically necessary, reference the FDA-approved dosing range, and explain why the plan's limit is inadequate for this patient.
• Prior treatment history: Dates, dosages tried, and documented outcomes or adverse effects of lower quantities or alternative regimens.
• Clinical severity documentation: Chart entries reflecting symptom burden, functional impairment, and response to current therapy.

## Criteria-Mapping Structure

Create a side-by-side table:

| Humana Requirement | Patient Evidence | |---|---| | Copy each criterion from Humana's published quantity-limit policy | Cite the specific chart note, date, and clinician statement that satisfies it | | Confirm quantity falls within FDA-approved range | Reference the prescribing label's dosing section; include prescriber attestation |

Address every criterion listed in the policy. Unanswered criteria are the most common reason appeals fail at the reconsideration stage.